S-1 with leucovorin for gastric cancer: how far can it go?

Affiliations

¹ National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan.
² National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: leochen@nhri.org.tw.

Comment

Tsang-Wu Liu et al. Lancet Oncol. 2016 Jan.

. 2016 Jan;17(1):12-4.

doi: 10.1016/S1470-2045(15)00478-7. Epub 2015 Nov 28.

¹ National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan.
² National Institute of Cancer Research, National Health Research Institutes, Tainan 70456, Taiwan; Department of Internal Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: leochen@nhri.org.tw.

No abstract available

Comment on

S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, Tsuji A, Nakajima TE, Gotoh M, Machida N, Bando H, Esaki T, Emi Y, Sekikawa T, Matsumoto S, Takeuchi M, Boku N, Baba H, Hyodo I. Hironaka S, et al. Lancet Oncol. 2016 Jan;17(1):99-108. doi: 10.1016/S1470-2045(15)00410-6. Epub 2015 Nov 28. Lancet Oncol. 2016. PMID: 26640036 Clinical Trial.